Send me real-time posts from this site at my email

Watchlist Update: 7-10 - HZNP - Horizon Therapeutics - Analyst Comments

TIGER'S TAKE:  On our trading list. Good biotech name for the longer term with a decent pipeline. Good for buying dips and selling peaks as well.    $HZNP

Horizon Pharma transition ahead of launch not reflected in shares, says Stifel

After Horizon Pharma announced that it has submitted a biologics license application, or BLA, to the FDA for teprotumumab for the treatment of active thyroid eye disease, Stifel analyst Annabel Samimy noted that priority review was requested and she said it is likely to be granted. A six-month review following a 60-day acceptance period could put teprotumumab on the market by the first half of 2020, said Samimy, who believes the company's transition to actively position themselves ahead of the teprotumumab launch has not yet been appropriately reflected in the shares. She reiterates a Buy rating and $35 price target on Horizon.

Source: (

$HZNP, Horizon Therapeutics Public Limited Company / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue